<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081908</url>
  </required_header>
  <id_info>
    <org_study_id>ATM</org_study_id>
    <nct_id>NCT05081908</nct_id>
  </id_info>
  <brief_title>Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.</brief_title>
  <acronym>ATM</acronym>
  <official_title>Hypofractionated Stereotactic Radiotherapy (Multisession Radiosurgery) in Residual/Recurrent Grade II Meningiomas: Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting&#xD;
      for patients who present post-surgical residual lesion or develop recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meningioma is the most common intracranial tumor (1). World Health Organization (WHO) grade&#xD;
      II (atypical) meningioma recurs more frequently than WHO grade I (benign) meningioma, and&#xD;
      patients with subtotally resected atypical meningioma should be treated with adjuvant&#xD;
      radiation therapy (2). However, many atypical meningiomas can be gross totally resected, and&#xD;
      whether to administer radiation to this population remains unclear. Apart from extent of&#xD;
      resection, clinical characteristics such as age and gender and tumor-related characteristics&#xD;
      such as tumor size and location have poor predictive capacity to determine which lesions will&#xD;
      recur.&#xD;
&#xD;
      The lack of professional consensus on the role of adjuvant radiation therapy (RT) derived&#xD;
      from the heterogeneity and retrospective nature of the published data: standard fractionation&#xD;
      fails to demonstrate a benefit in term of local control and survival.&#xD;
&#xD;
      Recent advances in radiotherapy technology (staged radiosurgery) give the possibility to&#xD;
      reach high dose levels only in tumor volume and in the same time to save the surrounding&#xD;
      healthy tissues.&#xD;
&#xD;
      The purpose of this study is to verify the related toxicity of a new radiotherapy protocol&#xD;
      and as second end point to evaluate the efficacy on disease local control at 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Actual">May 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological side effects</measure>
    <time_frame>through study completion, up to 2 year</time_frame>
    <description>Frequency of neurological side effects related to the radiosurgical treatment, evaluated according with CTCAE scale at every follow-up (4 months post-treatment, then every 6 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>through study completion, up to 2 year</time_frame>
    <description>The rate of tumor response defined as follow on the basis of modification of MRI imaging evaluated also with advanced RM techniques:Partial response (PR) is defined as 20%, decrease in the volumetric size of the lesion on MRI; stable disease (SD) as no change in the size of the lesion; progressive disease (PD) increase in any volumetric size of the lesion, confirmed at least a the following two consecutive MR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Meningioma Atypical</condition>
  <arm_group>
    <arm_group_label>Multisession radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiosurgery</intervention_name>
    <description>Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife</description>
    <arm_group_label>Multisession radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients had residual or recurrent atypical meningioma (grade II) after surgery&#xD;
             (Simpson score)&#xD;
&#xD;
          -  Age: ≥ 18 years old&#xD;
&#xD;
          -  Karnofsky performance Status ( KPS) ≥ 70&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Neurofibromatosis type 2 (NF2)&#xD;
&#xD;
          -  Concomitant aggressive haematological or solid neoplasm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Renato Mantegazza, MD</last_name>
    <phone>+39022394</phone>
    <phone_ext>2321</phone_ext>
    <email>crc@istituto-besta.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>UOC Radioterapia</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fariselli, MD</last_name>
      <email>laura.fariselli@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Laura Fariselli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63. doi: 10.1093/neuonc/nou223.</citation>
    <PMID>25304271</PMID>
  </reference>
  <reference>
    <citation>Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG 2nd. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009 Jan;64(1):56-60; discussion 60. doi: 10.1227/01.NEU.0000330399.55586.63.</citation>
    <PMID>19145156</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atypical meningioma</keyword>
  <keyword>radiosurgery</keyword>
  <keyword>multisession radiosurgery</keyword>
  <keyword>recurrence meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

